Amyloidosis and the lung

Chronic Respiratory Disease

Volumn 3, Issue 4, 2006, Pages 203-214

  Lachmann, H J ^a   Hawkins, P N ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

AA; AL; Amyloidosis; Localised; Nodular pulmonary; Respiratory; Tracheobronchial

Indexed keywords

AMYLOID A PROTEIN; CORTICOSTEROID; DEXAMETHASONE; DIMETHYL SULFOXIDE; DOXORUBICIN; MELPHALAN; PLASMA PROTEIN; PREDNISOLONE; VINCRISTINE;

AMYLOIDOSIS; CHRONIC RESPIRATORY TRACT DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; ENDOSCOPIC SURGERY; HISTOPATHOLOGY; HUMAN; INCIDENCE; LARYNX DISORDER; LOW LEVEL LASER THERAPY; LUNG PARENCHYMA; LYMPHADENOPATHY; NEEDLE BIOPSY; PRIORITY JOURNAL; PROTEIN FOLDING; RADIODIAGNOSIS; RESPIRATORY SYSTEM; REVIEW; STEM CELL TRANSPLANTATION; TISSUE STRUCTURE; TRACHEOBRONCHIAL TREE;

AMYLOIDOSIS; HUMANS; LUNG; LUNG DISEASES;

EID: 33845306300     PISSN: 14799723     EISSN: 14799731     Source Type: Journal    
DOI: 10.1177/1479972306070066     Document Type: Review

References (135)

1. Westermark P, Araki S, Benson MD et al. Nomenclature of amyloid fibril proteins. Amyloid: The International Journal of Experimental and Clinical Investigation 1999; 6: 63-66.
2. Puchtler H, Sweat F, Levine M. On the binding of Congo red by amyloid. Journal of Histochemistry and Cytochemistry 1962; 10: 355-64.
3. Cathcart ES, Cohen AS. The identification of two new components common to a variety of amyloid tissues. Journal of Clinical Investigation 1966; 45: 995.
4. Harada M, Isersky C, Cuatrecasas P et al. Human amyloid protein: chemical variability and homogeneity. Journal of Histochemistry and Cytochemistry 1971; 19: 1-15.
5. Blake CCF, Serpell LC. Synchrotron X-ray studies suggest that the core of the transthyretin amyloid fibril is a continuous b-sheet helix. Structure 1996; 4: 989-98.
6. Sunde M, Serpell LC, Bartlam M, Fraser PE, Pepys MB, Blake CCF. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. Journal of Molecular Biology 1997; 273: 729-39.
7. Pepys MB, Booth DR, Hutchinson WL, Gallimore JR, Collins PM, Hohenester E. Amyloid P component. A critical review. Amyloid: The International Journal of Experimental and Clinical Investigation 1997; 4: 274-95.
8. 123I-labeled serum amyloid P component. New Engl J Med 1990; 323: 508-13.
9. Pepys MB, Hawkins PN. Amyloidosis. In Warrell DA, Cox TM, Firth JD, Benz EJ Jr eds. Oxford textbook of medicine. Oxford University Press, 2003; 162-73.
10. Hawkins PN. Studies with radiolabelled serum amyloid P component provide evidence for turnover and regression of amyloid deposits in vivo. Clinical Science 1994; 87: 289-95.
11. Lowenstein J, Gallo G. Remission of the nephrotic syndrome in renal amyloidosis. New Engl J Med 1970; 282: 128-32.
12. Paraf A, Caste T, Rautureau J. La regression de l'amylose. Disparition d'une amylose hepatique massive apres nephrectomie pour cancer. Presse Medicale 1970; 78: 547-48.
13. Cohen HJ, Lessin LS, Hallal J, Burkholder P. Resolution of primary amyloidosis during chemotherapy. Ann Intern Med 1975; 82: 466-73.
14. Dikman SH, Kahn T, Gribetz D, Churg J. Resolution of renal amyloidosis. American Journal of Medicine 1977; 63: 430-33.
15. Falck HM, Törnroth T, Skrifvars B, Wegelius O. Resolution of renal amyloidosis secondary to rheumatoid arthritis. Acta Med Scand 1979; 205: 651-56.
16. Kyle RA, Wagoner RD, Holley KE. Primary systemic amyloidosis. Resolution of the nephrotic syndrome with melphalan and prednisolone. Archives of Internal Medicine 1982; 142: 1445-47.
17. Gertz MA, Kyle RA. Response of primary hepatic amyloidosis to melphalan and prednisone: a case report and review of the literature. Mayo Clinic Proceedings 1986; 61: 218-23.
18. Schattner A, Varon D, Green L, Hurwitz N, Bentwich Z. Primary amyloidosis with unusual bone involvement: reversibility with melphalan, prednisone, and colchicine. American Journal of Medicine 1986; 86: 347-48.
19. Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J. Colchicine in the prevention and treatment of amyloidosis of familial Mediterranean fever. New Engl J Med 1986; 314: 1001-1005.
20. Sezer O, Schmid P, Shweigert M et al. Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support. Bone Marrow Transplant 1999; 23: 967-69.
21. Gertz MA, Kyle RA. Hepatic amyloidosis (primary [AL], immunoglobulin light chain): the natural history in 80 patients. American Journal of Medicine 1988; 85: 73-80.
22. McPherson RA, Orstad JW, Ugoretz RJ, Wolf PL. Coagulation in amyloidosis: combined deficiency of factors IX and X. American Journal of Hematology 1977; 3: 225-35.
23. Triplett DA, Bang NU, Harms CS, Benson MD, Miletich JP. Mechanism of acquired factor X deficiency in primary amyloidosis. Blood 1977; 50(Suppl. 1): 285.
24. Griepp PR, Kyle RA, Bowie EJW. Factor X deficiency in amyloidosis: a critical review. American Journal of Hematology 1981; 11: 443-50.
25. Mumford AD, O'Donnell J, Gillmore JD, Manning RA, Hawkins PN, Laffan M. Bleeding symptoms and coagulation abnormalities in 337 patients with AL amyloidosis. Br J Haematol 2000; 110: 454-60.
26. Kaw YT, AR E. Solitary pleural amyloid nodules occurring as coin lesions diagnosed by fine-needle aspiration biopsy. Diagn Cytopathol 1991; 7: 304-307.
27. Dahlgren SE, Lewenhaupt A, CO O. Fine needle biopsy diagnosis in nodular pulmonary amyloidosis. Acta Path Microbiol Scand 1970; 78: 1-5.
28. Shah PL, Gillmore JD, Copley SJ et al. The importance of complete screening for amyloid fibril type and systemic disease in patients with amyloidosis in the respiratory tract. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 134-42.
29. Linke RP, Gärtner HV, Michels H. High-sensitivity diagnosis of AA amyloidosis using Congo red and immunohistochemistry detects missed amyloid deposits. Journal of Histochemistry and Cytochemistry 1995; 43: 863-69.
30. Tan SY, Pepys MB. Amyloidosis. Histopathology 1994; 25: 403-14.
31. Lachmann HJ, Booth DR, Booth SE et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. New Engl J Med 2002; 346: 1786-91.
32. Lachmann HJ, Gallimore R, Gillmore JD et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003; 122: 78-84.
33. Miyamoto TKT, Makiyama M, Kitada S, Fujishima M, Hagari Y, Mihara M. Monoclonality of infiltrating plasma cells in primary pulmonary nodular amyloidosis: detection with polymerase chain reaction. J Clin Pathol 1999; 52: 464-67.
34. Hind CRK, Gibson DG, Lavender JP, Pepys MB. Non-invasive demonstration of cardiac involvement in acquired forms of systemic amyloidosis. Lancet 1984; i: 1417.
35. Klein AL, Halle LK, Burstow DJ et al. Doppler characterization of left ventricular diastolic function in cardiac amyloidosis. Journal of the American College of Cardiology 1989; 13: 1017-26.
36. Klein AL, Halle LK, Burstow DJ et al. Comprehensive Doppler assessment of right ventricular diastolic function in cardiac amyloidosis. Journal of the American College of Cardiology 1990; 15: 99-108.
37. Vigushin DM, Clesham G, Hawkins PN et al. Echocardiography in systemic AL amyloidosis. In Kisilevsky R, Benson MD, Frangione B, Gauldie J, Muckle TJ, Young ID eds. Amyloid and amyloidosis 1993. Parthenon Publishing, 1994; 268-70.
38. de Beer FC, Mallya RK, Fagan EA, Lanham JG, Hughes GRV, Pepys MB. Serum amyloid A protein (SAA) concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet 1982; ii: 231-34.
39. Schnitzer TJ, Ansell BM. Amyloidosis in juvenile chronic polyarthritis. Arthritis and Rheumatism 1977; 20: 245-52.
40. Myllykangas-Luosujärvi R, Aho K, Kautiainen H, Hakala M. Amyloidosis in a nationwide series of 1666 subjects with rheumatoid arthritis who died during 1989 in Finland. Rheumatology 1999; 38: 499-503.
41. Pras M, Schubert M, Zucker-Franklin D, Rimon A, Franklin EC. The characterisation of soluble amyloid prepared in water. J Clin Invest 1968; 47: 924-33.
42. 1) from human high density lipoprotein. Biochemistry 1982; 21: 3298-303.
43. Yamada T. Serum amyloid A (SAA): a concise review of biology, assay methods and clinical usefulness. Clin Chem Lab Med 1999; 37: 381-88.
44. Castleman B, Iverson L, Menendez P. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 1956; 9: 822-30.
45. Palestro G, Turrini F, Pagano M, Chiusa L. Castleman's disease. Adv Clin Path 1999; 3: 11-22.
46. McCarty MJ, Vukelja SJ, Banks PM, Weiss RB. Angiofollicular lymph node hyperplasia (Castleman's disease). Cancer Treat Rev 1995; 21: 291-310.
47. Parez N, Bader-Meunier B, Roy CC, Dommergues JP. Paediatric Castleman disease: report of seven cases and review of the literature. European Journal of Pediatrics 1999; 158: 631-37.
48. Lachmann HJ, Gilbertson JA, Gillmore JD, Hawkins PN, Pepys MB. Unicentric Castleman's disease complicated by systemic AA amyloidosis: a curable disease. Quarterly Journal of Medicine 2002; 95: 211-18.
49. Shah SPKM, Anibogu J, Miller A. Nodular amyloidosis of the lung from intravenous drug abuse: an uncommon cause of multiple pulmonary nodules. South Med J 1998; 91: 402-404.
50. Hawkins PN. Diagnosis and monitoring of amyloidosis. In Husby G ed. Baillière's clinical rheumatology: reactive amyloidosis and the acute phase response. Baillière Tindall, 1994; 635-59.
51. Gillmore JD, Lovat LB, Persey MR et al. Cumulative SAA production and outcome of AA amyloidosis. In Kyle RA, Gertz MA eds. Amyloid and amyloidosis 1998. Parthenon Publishing, 1999; 402-404.
52. Osserman EF, Takatsuki K, Talal N. The pathogenesis of "amyloidosis". Studies on the role of abnormal gammaglobuline and gammaglobulin fragments of the Bence Jones (L-polypeptide) types in the pathogenesis of "primary" and "secondary" amyloidosis associated with plasma cell myeloma. Seminars in Hematology 1964; 1: 3.
53. Linder J, Silberman HR, Croher BP. Amyloidosis complicating hairy cell leukaemia. American Journal of Clinical Pathology 1982; 78: 864-67.
54. Glenner GG, Ein D, Eaves ED, Bladen HA, Terry W, Page DL. Creation of "amyloid" fibrils from Bence Jones protein in vitro. Science 1971; 174: 712-14.
55. Glenner GG, Terry W, Harada M, Isersky C, Page D. Amyloid fibril proteins: proof of homology with immunoglobulin light chains by sequence analyses. Science 1971; 172: 1150-51.
56. Glenner GG, Ein D, Terry WD. The immunoglobulin origin of amyloid. American Journal of Medicine 1972; 52: 141-47.
57. Koss MN, Holchholzer L, Moran CA, Frizzera G. Pulmonary plasmacytomas: a clinicopathologic and immunohistochemical study of five cases. Ann Diagn Pathol 1998; 2: 1-11.
58. Buxbaum J. Aberrant immunoglobulin synthesis in light chain amyloidosis. Free light chain and light chain fragment production by human bone marrow cells in short-term tissue culture. J Clin Invest 1986; 78: 798-806.
59. Buxbaum J. Mechanisms of disease: monoclonal immunoglobulin deposition. Amyloidosis, light chain deposition disease, and light and heavy chain deposition disease. Hematol Oncol Clin North Am 1992; 6: 323-46.
60. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Seminars in Hematology 1995; 32: 45-59.
61. Gertz MA, Kyle RA. Primary systemic amyloidosis - a diagnostic primer. Mayo Clinic Proceedings 1989; 64: 1505-19.
62. Dubrey SW, Cha K, Anderson J et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. Quarterly Journal of Medicine 1998; 91: 141-57.
63. Gertz MA, Kyle RA. Prognostic value of urinary protein in primary systemic amyloidosis (AL). American Journal of Clinical Pathology 1990; 94: 313-17.
64. Lovat LB, Pepys MB, Hawkins PN. Amyloid and the gut. Digestive Diseases 1997; 15: 155-71.
65. Berk JL, O'Regan A, Skinner M. Pulmonary and tracheobronchial amyloidosis. Semin Respir Crit Care Med 2002; 23 155-66.
66. Berk JL, Keane J, Seldin DC et al. Persistent pleural effusions in primary systemic amyloidosis. Chest 2003; 124: 969-77.
67. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002; 99: 4276-82.
68. Hawkins PN. The diagnosis, natural history and treatment of amyloidosis. The Goulstonian Lecture 1995. J R Coll Physicians Lond 1997; 31: 552-60.
69. Gertz MA, Kyle RA, Greipp PR. Response rates and survival in primary systemic amyloidosis. Blood 1991; 77: 257-62.
70. Kyle RA, Gertz MA, Greipp PR et al. Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood 1999; 93: 1062-66.
71. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. New Engl J Med 1997; 336: 1202-207.
72. Wardley AM, Jayson GC, Goldsmith DJ, Venning MC, Ackrill P, Scarffe JH. The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone. British Journal of Cancer 1998; 78: 774-76.
73. Persey MR, Lovat LB, Apperley JF, Madhoo S, Pepys MB, Hawkins PN. Intensive chemotherapy for AL amyloidosis. Br J Rheumatol 1996; 35(Suppl 1): 12.
74. Gillmore JD, Apperley JF, Pepys MB, Hawkins PN. High dose chemotherapy for systemic AL amyloidosis. Kidney Int 1999; 55: 2103.
75. Gertz MA, Lacy MQ, Gastineau DA et al. Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). Bone Marrow Transplant 2000; 26: 963-69.
76. Sanchorawala V, Wright DG, Seldin DC et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 2001; 28: 637-42.
77. Moreau P, Leblond V, Bourquelot P et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol 1998; 101: 766-69.
78. Utz JP, Swensen SJ, Gertz MA. Pulmonary amyloidosis. The Mayo Clinic experience from 1980 to 1993. Ann Intern Med 1996; 124: 407-413.
79. Thompson PJ, Citron K. Amyloid and the lower respiratory tract. Thorax 1983; 38: 84-87.
80. Gillmore JD, Hawkins PN. Amyloidosis and the respiratory tract. Thorax 1999; 54: 444-51.
81. Pasternak S, White VA, Gascoyne RD, Perry SR, Johnson RL, Rootman J. Monoclonal origin of localised orbital amyloidosis detected by molecular analysis. Br J Ophthalmol 1996; 80: 1013-17.
82. Hamidi Asl K, Liepnieks JJ, Bihrle R, Benson MD. Local synthesis of amyloid fibril precursors in AL amyloidosis of the urinary tract. Amyloid: Int J Exp Clin 1998; 5: 49-54.
83. Hamidi Asl K, Leipnieks JJ, Nakamura A, Benson MD. Organ-specific (localized) synthesis of Ig light chain amyloid. J Immunol 1999; 162: 5556-60.
84. Livneh A, Shtrasburg S, Martin BM, Baniel J, Gal R, Pras M. Light chain amyloidosis of the urinary bladder. A site restricted deposition of an externally produced immunoglobulin. J Clin Pathol 2001; 54: 920-23.
85. Westermark P, Sletten K, Pitkanen P, Natvig J, Lindholm C. Localised laryngeal amyloidosis: partial characterization of an amyloid fibril protein AL. Mol Immunol 1982; 19: 447-50.
86. Lewis JE, Olsen KD, Kurtin PJ, Kyle RA. Laryngeal amyloidosis: a clinicopathologic and immunohistochemical review. Otolaryngol Head Neck Surg 1992; 106: 372-77.
87. Murdoch IE ST, Moseley I, Hawkins PN et al. Primary localised amyloidosis of the orbit. Br J Ophthalmol 1996; 80: 1083-86.
88. Woollons A, Black MM. Nodular localized primary cutaneous amyloidosis: a long-term follow-up study. Br J Dermatol 2001; 145: 105-109.
89. Thompson LD, Derringer GA, Wenig BM. Amyloidosis of the larynx: a clinicopathologic study of 11 cases. Mod Pathol 2000; 13: 528-35.
90. Tirzaman O, Wahner-Roedler DL, Malek RS, Sebo TJ, Li CY, Kyle RA. Primary localized amyloidosis of the urinary bladder: a case series of 31 patients. Mayo Clin Proc 2000; 75: 1264-68.
91. Berg AM, Troxler RF, Grillone G et al. Localized amyloidosis of the larynx: evidence for light chain composition. Ann Otol Rhinol Laryngol 1993; 102: 884.
92. McAlpine JC, Fuller A. Localised laryngeal amyloidosis, a report of a case with a review of the literature. J Laryngol Otol 1964; 78: 296-314.
93. New G. Amyloid tumours in the upper air passages. Laryngoscope 1919; 29: 327-41.
94. Siddachari R, Chaukar DA, Pramesh CS, Naresh KN, de Souza CE, Douzak AK. Laryngeal Amyloielosis. J Otolaryngol 2005; 34: 60-63.
95. Chow LT, Chow W, Shum D. Fatal massive upper respiratory tract haemorrhage: an unusual complication of localised amyloidosis of the larynx. J Laryngol Otol 1993; 107: 51-53.
96. D'Arey F. Localised amyloidosis of the larynx. J Laryngol Otol 1972; 94: 494-97.
97. Walker P, Courey MS, Ossoff R. Staged endoscopic treatment of laryngeal amyloidosis. Otolaryngol Head Neck Surg 1996; 114: 801-805.
98. Finn D, Farmer J. Management of amyloidosis of the larynx and trachea. Arch Otolaryngol Head Neck Surg 1982; 108: 54-56.
99. McIlwain JC, Shepperd H. Laser treatment of promary amyloidosis of the larynx. J Laryngol Otol 1986; 100: 1079-80.
100. Piazza C, Cavaliere S, Foccoli P, Toninelli C, Bolzoni A, Peretti G. Endoscopic management of laryngo-tracheobronchial amyloidosis: a series of 32 patients. Eur Arch Otorhinolaryngol 2003; 260: 349-54.
101. Mitrani M, Biller H. Laryngeal amyloidosis. Laryngoscope 1985; 95: 1346-47.
102. de Sousa MM, Vital C, Ostler D et al. Apolipoprotein AI and transthyretin as components of amyloid fibrils in a kindred with apoAI Leu178His amyloidosis. American Journal of Pathology 2000; 156: 1911-17.
103. Hamidi Asl K, Liepnieks JJ, Nakamura M, Parker F, Benson MD. A novel apolipoprotein A-1 variant, Arg173Pro, associated with cardiac and cutaneous amyloidosis. Biochemical and Biophysical Research Communications 1999; 257: 584-88.
104. Hamidi Asl L, Liepnieks JJ, Hamidi Asl K et al. Hereditary amyloid cardiomyopathy caused by a variant apolipoprotein A1. American Journal of Pathology 1999; 154: 221-27.
105. Assmann G, Schmitz G, Funke H, von Eckardstein A. Apolipoprotein A-I and HDL deficiency. Current Opinion in Lipidology 1990; 1: 110-15.
106. Westermark P, Mucchiano G, Marthin T, Johnson KH, Sletten K. Apolipoprotein A1-derived amyloid in human aortic atherosclerotic plaques. American Journal of Pathology 1995; 147: 1186-92.
107. Booth DR, Tan SY, Booth SE et al. Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein AI gene. J Clin Invest 1996; 97: 2714-21.
108. Nichols WC, Gregg RE, Brewer HBJ, Benson MD. A mutation in apolipoprotein A-I in the Iowa type of familial amyloidotic polyneuropathy. Genomics 1990; 8: 318-23.
109. Cordier JF, Loire R, Brune J. Amyloidosis of the lower respiratory tract. Clinical and pathologic features in a series of 21 patients. Chest 1986; 90: 827-31.
110. Sakula A. Tracheobronchopathia osteochondroplastica: its relationship to primary tracheobronchial amyloidosis. Thorax 1968; 23: 105-10.
111. Jones AW, Chatterji A. Primary tracheobronchial amyloidosis with tracheobronchopathia osteochondroplastica. Br J Dis Chest 1977; 71: 268-72.
112. Neinhuis DM, Prakash UB, Edell ES. Tracheobronchopathia osteochondroplastica. Ann Otol Rhinol Laryngol 1990; 99: 689-94.
113. O'Regan A, Felon HM, Beamis JF, Steele MP, Skinner MD, Berk J. Tracheobronchial amyloidosis: the Boston university experience from 1984 to 1999. Medicine (Baltimore) 2000; 79: 69-79.
114. Farrell M, McAdams HP, Erasmus JJ. A 27-year-old woman with cough, dyspnea, and wheezing. Chest 1999; 116: 557-59.
115. Cotton RE, Jackson JW. Localised tumours of the lung simulating neoplasm. Thorax 1964; 19: 97-103.
116. Monroe AT, Walia R, Zlotecki RA, Jantz MA. Tracheobronchial amyloidosis: a case report of successful treatment with external beam radiation therapy. Chest 2004; 125: 784-89.
117. Nugent AM, Elliott H, McGuigan JA, Varghese YG. Pulmonary amyloidosis: treatment with laser therapy and systemic steroids. Respir Med 1996; 90: 433-35.
118. Breuer R, Simpson GT, Rubinow A, Skinner M, Cohen AS. Tracheobronchial amyloidosis: treatment by carbon dioxide laser photoresection. 1985; 40: 870-71.
119. Kurrus JA, Hayes JK, Hoidal JR, Menendez MM, Elstad MR. Radiation therapy for tracheobronchial amyloidosis. Chest 1998; 114: 1489-92.
120. Dahl KA, Kernstine KH, Vannatta TL, Karwal MW, Thomas KW, Schraith DS. Tracheobronchial amyloidosis: A surgical disease with long-term consequences. J Thorac Cardiovasc Surg 2004; 128: 789-92.
121. Hui AN, Koss MN, Hochholzer L, Wehunt WD. Amyloidosis presenting in the lower respiratory tract. Clinicopathologic, radiologic, immunohistochemical, and histochemical studies on 48 cases. Arch Pathol Lab Med 1986; 110: 212-18.
122. Himmelfarb E, Wells S, Rabinowitz JG. The radiologic spectrum of cardiopulmonary amyloidosis. Chest 1977; 72: 327-32.
123. Urban BA, Fishman EK, Goldman SM et al. CT evaluation of amyloidosis: spectrum of disease. 1993; 13: 1295-308.
124. Ayuso MC, Gilabert R, Bombi JA, Salvador A. CT appearance of localized pulmonary amyloidosis. J Comput Assist Tomogr 1987; 11: 197-99.
125. Rubinow ACB, Cohen AS, Rigden BG, Brody JS. Localized amyloidosis of the lower respiratory tract. Am Rev Respir Dis 1978; 118: 603-11.
126. Masaki Y, Sugai S. Lymphoproliferative disorders in Sjogren's syndrome. Autoimmun Rev 2004; 3: 175-82.
127. Jeong Y, Lee K, Chung MP et al. Amyloidosis and lymphoproliferative disease in Sjogren syndrome thin-section comuted tomography findings and histopathologic comparisions. J Comput Assist Tomogr 2004; 28: 776-81.
128. Kambouchner M, Godmer P, Guillevin L, Raphael M, Droz D, Martin A. Low grade marginal zone B cell lymphoma of the breast associated with localised amyloidosis and corpora amylacea in a woman with long standing primary Sjogren's syndrome. J Clin Pathol 2003; 56: 74-77.
129. Delevaux I, Andre M, Amoura Z, Kemeny JL, Piette JC, Aumaitre O. Concomitant diagnosis of primary Sjogren's syndrome and systemic AL amyloidosis. Ann Rheum Dis 2001; 60: 694-95.
130. Celli BR, Rubinow A, Cohen AS, Brody JS. Patterns of pulmonary involvement in systemic amyloidosis. Chest 1978; 74: 543-47.
131. Smith R, Hutchins GM, Moore GW, Humphrey RL. Type and distribution of pulmonary parenchymal and vascular amyloid. Correlation with cardiac amyloid. Am J Med 1979; 66: 96-104.
132. Gallego F, Canelas J. Hilar enlargment in amyloidosis. N Engl J Med 1974; 291: 531.
133. Zatloukal P, Bezdiek P, Schimonova M, Tesarova P, Slovakaova A. Waldenstrom's macroglobulinemia with pulmonary amyloidosis. Respiration 1998; 65: 414-16.
134. Gross B. Radiographic manifestations of lymph node involvement in amyloidosis. Radiology 1981; 138: 11-14.
135. Lachmann HJ, Hawkins PN. Novel pharmacological strategies in amyloidosis. Nephron Clin Pract 2003; 94: c85-88.